Elidel

Phase 3Small molecule

Bayer

Elidel is one of 68 small molecule programs targeting Atopic Dermatitis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Atopic DermatitisActive, not recruiting

Seborrheic DermatitisActive, not recruiting

Cutaneous Lupus ErythematosusActive, not recruiting

Atopic DermatitisPhase 3

Active, not recruiting

Seborrheic DermatitisPhase 2

Active, not recruiting

Cutaneous Lupus ErythematosusPreclinical

Active, not recruiting

Competition

Competitive Landscape

508 competitors in Atopic Dermatitis

#DrugCompanyPhaseTrials

Olumiant

Eli Lilly

Phase 3

11 2

Rezzayo

Roche

Phase 3

10 3

Daliresp

AstraZeneca

Phase 3

4 4

Immunotherapy

Bristol-Myers Squibb

Phase 3

1 5

Broncho-Vaxom

OOM Pharma SA

Phase 3

1 6

Elidel

Bayer

Phase 3

4 7

Adquey

AAcrotech Biopharma Inc.

Phase 3

2 8

EBGLYSS

Eli Lilly

Preclinical

23 9

Cibinqo

Pfizer

Preclinical

11 10

Prograf

VVeloxis Pharmaceuticals

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Atopic Dermatitis4 trials

A Clinical Study in Children and Adolescents With Mild to Moderate Atopic Dermatitis

Completed· Bayer logo

Bayer·Phase 4·NCT00568412·80 enrolled

Study of Generic Pimecrolimus Cream, 1% in the Treatment of Mild to Moderate Atopic Dermatitis

Completed·GGlenmark Pharmaceuticals Ltd. India·Phase 3·NCT02896101·755 enrolled

Epiceram Versus Elidel for Treatment of Mild to Moderate Atopic Dermatitis

Completed·CCeragenix Pharmaceuticals·Phase 4·NCT00460083·35 enrolled

Show 1 more trial

LEO 29102 Cream in the Treatment of Atopic Dermatitis

Completed· LEO Pharma logo

LEO Pharma·Phase 2·NCT01037881·183 enrolled

Treatment1 trial

Efficacy of Topical Pimecrolimus in the Treatment of Pityriasis Alba

Unknown status·SSt Joseph University, Beirut, Lebanon·Phase 2/3·NCT03834935·40 enrolled

Cutaneous Lupus Erythematosus1 trial

Cutaneous Lupus Erythematosus and Elidel

Withdrawn·UUniversity of Leipzig·N/A·NCT00222183

Seborrheic Dermatitis1 trial

A 4 Week Study of Elidel (Pimecrolimus) for the Treatment of Seborrheic Dermatitis

Completed·DDermatology Specialists Research·Phase 2·NCT00403559·113 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Elidel. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Elidel compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Elidel. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bayer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Bayer

Elidel

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Atopic Dermatitis4 trials

Treatment1 trial

Cutaneous Lupus Erythematosus1 trial

Seborrheic Dermatitis1 trial

References

Drug Info

Quick Facts

Related News